Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen
References (82)
- et al.
Epidemiology and outcomes of osteoporotic fractures
Lancet.
(2002) Economic impact of fractures
Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerg ing role of intermittent therapy
Clin Ther.
(2005)- et al.
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys
Bone
(2003) - et al.
Efficacy and safety of ibandronate given by intravenous injec tion once every 3 months
Bone
(2004) - et al.
The efficacy of 48-week oral ibandronate treatment in post menopausal osteoporosis when taken 30 versus 60 minutes before breakfast
Bone
(2003) - et al.
Osteonecrosis of the jaws associated with the use of bis phosphonates: A review of 63 cases
J Oral Maxillofac Surg.
(2004) - et al.
Compliance with drug therapies for the treatment and prevention of osteoporosis
Maturitas
(2004) - et al.
The impact of reducing dose frequency on health outcomes
Clin Ther.
(2003) - et al.
Effect of dosing frequency on bisphosphonate medication adher ence in a large longitudinal cohort of women
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom
Clin Ther.
The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management
Clin Ther.
Summary of meta-analyses of therapies for postmenopausal os teoporosis and the relationship between bone density and fractures
Endocrinol Metab Clin North Am.
The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial
Ann Oncol.
Oral ibandronate improves bone pain and preserves quality of life in pa tients with skeletal metastases due to breast cancer
Pain
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
Ann Oncol.
Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Eur J Cancer.
Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials
Clin Ther.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group
World Health Organ Tech Rep Ser.
Diet, nutrition and the prevention of chronic diseases
World Health Organ Tech Rep Ser.
The State of Osteoporosis and Low Bone Mass
Bone Health and Osteoporosis: A Report of the Surgeon General
Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study
J Am Geriatr Soc.
Mortality risk after hip fracture. 2003
J Orthop Trauma.
Treatment of postmenopausal osteoporosis
Pharmacotherapy
Oral antiresorptive therapy
Curr Rheumatol Rep.
Prevention of postmenopausal bone loss and treatment of osteoporosis
Semin Reprod Med.
Osteoporosis and osteomalacia
The use of bisphosphonates in the treatment of osteoporosis
Curr Opin Rheumatol.
Ibandronate
Drugs
Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing
Osteoporos Int.
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
J Bone Miner Res.
Ibandronate: A clinical pharmacological and pharmacokinetic up date
J Clin Pharmacol.
Ibandronate: Serum kinetics, tissue distribution and bind ing to bone following intravenous bolus injection
Calcif Tissue Int.
Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties
J Bone Miner Res.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
J Bone Miner Res.
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study
J Clin Endocrinol Metab.
Monthly oral ibandronate therapy in postmenopausal osteo porosis: 1-Year results from the MOBI LE study
J Bone Miner Res.
Cited by (23)
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial
2019, European Journal of CancerCitation Excerpt :Trials evaluating early assumption of adjuvant zoledronic acid [20–24] and risedronate [25–27] showed a statistically significant improvement of BMD and a bone loss prevention over time. In our study, patients' treatment tolerance was in line with previously published experiences [28,29], with an expected dropout rate of 19.1% mainly due to patient's personal choice (41.2%) more than tolerance (29.4%) in the treatment arm (Fig. 1). No major adverse events were recorded during study's conduction, the main reported toxicities were arthralgia/myalgia and dyspepsia, with no significant differences between arms observed.
Drug induced osteonecrosis of the jaw
2015, Cancer Treatment ReviewsCitation Excerpt :Bisphosphonates have a well-established therapeutic role for the treatment and prevention of osteoporosis. Findings from randomized clinical studies [14–18] designed to evaluate the clinical efficacy of bisphosphonates in patients with osteoporosis demonstrated that their use resulted in about a 40–50% reduction in the risk of spine fractures and a 25% reduction in the risk of hip fractures accompanied by about a 5–8% increase in bone mass density (BMD). Moreover, clinical practice guidelines advocate treatment with bisphosphonates for the prevention of osteoporosis in patients receiving long term glucocorticoids as well as the prevention of skeletal related events (SREs, spinal cord compression, pathologic fractures, and radiation therapy) among patients with multiple myeloma or other solid tumors (breast, lung, prostate, etc…) that has metastasized to the bones.
Comparison of the pharmacokinetics, safety, and tolerability of vitamin D<inf>3</inf> in DP-R206 (150-mg ibandronate/24,000-IU vitamin D<inf>3</inf> Tablet) and as monotherapy (24,000 IU) in healthy male Korean adults
2014, Clinical TherapeuticsCitation Excerpt :Monthly dosing is associated with improved adherence compared with daily or weekly regimens. Once-monthly ibandronate therapy has significantly improved compliance compared with the weekly alendronate regimen.17 Therefore, monthly combined treatment with a bisphosphonate and vitamin D3 is convenient, effective, and safe for treating postmenopausal osteoporosis patients.
Osteoporosis in Men and Women
2010, Principles of Gender-Specific MedicineA new dose of bisphosphonate for the prevention and the treatment of the postmenopausal osteoporosis
2007, Revista Espanola de Enfermedades Metabolicas OseasTherapeutic adherence to bisphosphonates
2007, Biomedicine and Pharmacotherapy